<![CDATA[Introduction: Stroke is a major complication of atrial fibrillation, carries a high risk of recurrence. The likelihood of adverse effects from warfarin-drug interactions increases with the number of concurrent medications. Identifying these potential interactions is crucial. This study aimed to evaluate the impact of drug interactions on bleeding events and the incidence of recurrent stroke in patients with atrial fibrillation. Methods: This retrospective study tracked 314 stroke patients with atrial fibrillation at Dr. Sardjito and Dr. Moewardi General Hospital over one year who received warfarin at two hospitals from January 2015 to December 2019. Using purposive sampling, 50 patients were analyzed and divided into two groups, 11 with stroke recurrence and 39 without recurrence in one year of treatment. Statistical analyses, including chi-square tests and odds ratio calculations, were performed to assess factors influencing stroke recurrence. Results: In addition, major, moderate, and minor drug interactions were not significantly different p>0,05. Meanwhile, minor drug interaction correlated with bleeding event (p<0,05) and OR 0,1. The study underscored an elevated risk of bleeding associated with combinations such as warfarin-amiodarone, warfarin-clopidogrel, and various NSAIDs in major interaction analysis. Conclusion: The research highlights an increased risk of bleeding caused by interaction in combinations therapiest such as warfarin-amiodarone, warfarin-clopidogrel, and various NSAIDs. These findings stress the importance of careful evaluation and management of drug interactions to reduce adverse effects and enhance outcomes for patients with recurrent strokes with atrial fibrillation.]]>
